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Abstract
Embryonic stem cells (ESCs) have received tremendous attention because of their potential 
applications in regenerative medicine. Over the past two decades, intensive research has not only 
led to the generation of various types of cells from ESCs that can be potentially used for the 
treatment of human diseases, but also led to the formation of new concepts and breakthroughs that 
have significantly impacted our understanding of basic cell biology and developmental biology. 
Recent studies have revealed that ESCs and other types of pluripotent cells do not have a 
functional interferon (IFN)-based antiviral mechanism, challenging the idea that the IFN system is 
developed as the central component of antiviral innate immunity in all types of cells in vertebrates. 
This finding also provided important insight into a question that has been uncertain for a long 
time: whether or not the RNA interference (RNAi) antiviral mechanism operates in mammalian 
cells. An emerging paradigm is that mammals may have adapted distinct antiviral mechanisms at 
different stages of organismal development; the IFN-based system is mainly utilized by 
differentiated somatic cells while the RNAi antiviral mechanism may be used in ESCs. This paper 
discusses the molecular basis and biological implications for mammals to have different antiviral 
mechanisms during development.
Introduction
The defense response to pathogens is critically important for the growth, development, and 
survival of all living organisms. Over the course of evolution, different organisms have 
developed different defense mechanisms. Plants, fungi, and invertebrates defend themselves 
against viral infection with RNA interference (RNAi)1 while mammals have developed a 
protein-based interferon (IFN) system that can mount multiple forms of antiviral activities as 
a part of their innate immunity.2,3 For a long time, it has been uncertain whether the RNAi 
mechanism is utilized in mammals.4–7 Recent studies in mice suggest that RNAi may 
operate in embryonic stem cells (ESCs) and tissue cells at the early developmental stage.8,9 
An emerging hypothesis is that mammals appear to have adapted distinct antiviral strategies 
at different stages of development: differentiated somatic cells mainly use the IFN-based 
system while ESCs may utilize RNAi.4 This hypothesis is in part brought about by the 
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recent studies of ESCs and induced pluripotent cells (iPSCs), which somewhat unexpectedly 
provide important insight for our understanding of the antiviral innate immunity in mammals 
during development.
Over the past two decades, ESCs have attracted intensive research efforts because of their 
potential applications in regenerative medicine.10–12 Characterized by differentiation 
potential to various cell lineages (pluripotency) and unlimited proliferation capacity (self-
renewal), ESCs can be used as a promising cell source for cell-based therapies. The intensive 
research has not only led to the development of strategies that can generate various cell types 
from ESCs, but also led to the formation of new concepts and breakthroughs that have 
dramatically impacted our understanding of basic cell biology and developmental biology. 
The best example is the generation of iPSCs which has led to the concept of cell 
reprogramming and prompted us to rethink the notion of “terminally differentiated cells” 
defined in cell biology.13 The strongest evidence for the existence of the RNAi as an 
antiviral mechanism in mammals is derived from mouse ESCs (mESCs) and is largely 
attributed to their lack of IFN response,8 a property that has been recently characterized as 
part of an underdeveloped innate immunity in pluripotent cells.14 While new investigations 
have begun to uncover the molecular basis underlying this phenomenon, it is interesting to 
note that some studies dating back to about 40 years ago have already indicated that IFN-
based antiviral mechanism is different in pluripotent cells and differentiated somatic 
cells.15–17 As more and more pieces are being put together, the puzzle of why different 
antiviral mechanisms are utilized by mammalian cells at different developmental stages 
begins to make sense.
Recent studies have demonstrated that both human and mouse ESCs (hESCs and mESCs) as 
well as iPSCs have limited or no response to a wide range of infectious agents and 
inflammatory cytokines. Accumulating evidence suggests that underdeveloped innate 
immunity is a common feature of pluripotent cells. In a previous review,14 we have 
discussed this subject from the perspective of stem cell biology and regenerative medicine. 
This paper focuses on the discussion of the molecular basis and the rationale for the 
selective utilization of different antiviral mechanisms by ESCs and differentiated cells in 
mammals.
Overview of Different Mechanisms of Antiviral Immunity in Eukaryotes
RNAi antiviral mechanism
Originally discovered in C. elegans, the RNAi pathway has been recognized as a major 
antiviral mechanism in plants, fungi, and invertebrates.1,18 The basic process of this 
mechanism is that invading viral RNA are degraded into ~22-bp dsRNA duplexes (small 
interfering RNA, siRNA) by a host endoribonuclease known as Dicer. One strand of the 
siRNA is then loaded into the RNA-induced silencing complex (RISC), where it serves as a 
guide that directs RISC to the complementary region of invading viral RNA. Once bound, a 
member of the Argonaute (Ago) family with endonuclease activity (the catalytic component 
of RISC) cleaves the viral RNA, thereby inhibiting viral replication.1 This antiviral 
mechanism is highly specific and efficient to clear viral pathogens from the host without 
causing the destruction of infected cells. One would assume that the RNAi antiviral 
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mechanism developed in invertebrates would be conserved in vertebrates over the course of 
evolution. However, there is no convincing data to support this hypothesis, especially in 
mammalian species, in which the IFN-based antiviral mechanism has evolved.4,19
IFN-based antiviral innate immunity
Vertebrates have developed sophisticated immune systems that consist of innate and adaptive 
immunity. Innate immunity, presumably developed in most if not all cell types, is the first 
line of the organism’s defense against a broad range of pathogens in a non-specific manner. 
Adaptive immunity is the antigen-specific immune response that utilizes highly specialized 
immune cells (T cells and B cells) and provides the organism with the ability to mount an 
enhanced immune response to subsequent invasion of the same pathogens.20,21
At the cellular level, the innate immune response is mainly mediated by pattern recognition 
receptors, including toll-like receptors (TLRs) and retinoic acid–inducible gene I (RIG-I)-
like receptors (RLRs). A wide variety of infectious agents, including viral DNA/RNA and 
bacterial endotoxins, are recognized by different TLRs localized on the cell membrane or in 
endosomes.22 Viral RNAs in the cytosol are detected by RLRs, such as RIG-I and melanoma 
differentiation associated factor5 (MDA5).23 Recently, cGAS (cGMP-AMP synthase) has 
been identified as an important intracellular sensor for dsDNA viruses (or dsDNA that is 
produced by retroviruses). Infection of cells with dsDNA viruses activates cGAS and 
produces cyclic dinucleotide cGMP-AMP (cGAMP), which binds to and activates stimulator 
of interferon genes (STING), leading to IFN expression.24,25 Although different pathogens 
are recognized by distinct receptors and the signals are relayed by different molecules, the 
signal transduction eventually converges at the point of NFκB (nuclear factor κB) activation. 
Together with the other transcription factors, IRF (interferon regulatory factors) and AP1 
(activator protein1), NFκB activates the transcription of IFN, inflammatory cytokines, and 
other types of immune modulators (Figure 1).22,22,26
Based on the cellular origin, inducing agents, and cellular receptors, IFN are classified into 
types I, II, and III. Type I and type III IFN are produced by almost any type of cells upon 
viral infection, whereas type II IFN is produced mainly by natural killer cells and T 
lymphocytes.2,27,28 However, all three types of IFN share a common function in modulating 
the activity of the immune system. Through autocrine and paracrine mechanisms, IFN bind 
to the cell surface receptor complex (IFNAR), which triggers the activation of Janus tyrosine 
kinases (JAK1/TYK2) that phosphorylate signal transducers and activators of transcription 
(STAT1/2). Phosphorylated STAT1/2 and IRF3 form an IFN-stimulated gene factor 3 
(ISGF3) complex that translocates to the nucleus where it induces the expression of IFN-
stimulated genes (ISGs), which participate in antiviral activities via different 
mechanisms.2,27,29 Therefore, the IFN system, consisting of IFN expression and response 
mechanisms (Figure 1), has evolved as a powerful antiviral mechanism in vertebrates.
Intrinsic antiviral immunity
Intrinsic antiviral immunity refers to the form of innate immunity that directly restricts viral 
replication and assembly, thereby rendering a cell non-permissive to a specific class or 
species of viruses.30,31 Unlike pattern recognition receptors, which elicit antiviral activity by 
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inducing IFN, intrinsic immunity is provided by antiviral proteins that are constitutively 
expressed and ready to act in the cell, although they can be further upregulated by viral 
infection.30 Several virus-specific intrinsic antiviral factors and their mechanisms of action 
have been characterized.30,31 dsRNA-activated protein kinase R (PKR) and Ribonuclease L 
(RNase L), which are well known for their roles in the antiviral response,2,32 are also 
considered to be intrinsic antiviral factors with a broad antiviral spectrum. Since their 
expression is further upregulated by IFN upon viral infection, they are classified as ISGs as a 
part of IFN responses.2 However, differing from other ISGs, which are usually expressed at 
very low levels in uninfected cells, PKR and RNase L are expressed at high basal levels in 
uninfected cells and are immediately activated by invading viruses, therefore they can be 
mechanistically defined as intrinsic antiviral factors.30 Directly activated by viral RNA, PKR 
causes inhibition of both cellular and viral protein synthesis.33 RNase L is also known as 2'–
5' oligoadenylate synthetase (OAS)-dependent ribonuclease. Activated by viral dsRNA, OAS 
converts ATP to 2’–5’-linked oligoadenylates (2–5A), which then activate RNase L, leading 
to both cellular and viral RNA degradation, thereby preventing viral replication32 (Figure 1).
The Potential Function of RNAi Antiviral Mechanism in ESCs
The RNAi mechanism in mammals – a controversial issue in somatic cells and a rational 
alternate in ESCs
Extensive effort has been made to determine whether or not the RNAi mechanism is used by 
vertebrate animals, especially mammals. Synthetic siRNA transfected into mammalian cells 
can effectively inhibit viral replication and has been widely used as a technique for gene 
silencing, but there is little biochemical evidence that siRNA can be derived from viruses in 
infected cells.5 siRNA in organisms that lack the IFN system can be easily detected and 
characterized, but this is challenging in mammalian cells where multiple forms of antiviral 
activity mobilized by the IFN response make it difficult to assess the RNAi effect. In a 
recent study by Backes et al.,7 it was demonstrated that an engineered RNA virus that blocks 
the function of microRNA (miRNA) and siRNA did not replicate faster than the control 
virus in either cell culture or in a mouse model.7 Furthermore, human and mouse cells with a 
disrupted dcr gene, which are unable to generate siRNA or miRNA, did not show an 
apparent difference in viral replication from normal cells.34 The lack of biochemical and 
genetic evidence for the existence of siRNA suggest that the RNAi mechanism seems 
unlikely to play a role in antiviral immunity in mice or humans. However, studies in 
pluripotent cells present a different picture.
Using mESCs as a model system, Maillard et al.8 demonstrated that siRNA of viral origin 
with the features of bona fide siRNA were detected in mESCs infected with 
encephalomyocarditis virus or Nodamura virus, suggesting that the RNAi pathway is 
functional in mESCs. In a separate study, Li et al.9 reported that viral siRNA derived from 
Nodamura virus, identical to those detected in mESCs, were accumulated in infected 
newborn mice, supporting the possibility of a functional RNAi mechanism in vivo. Thus, 
while the physiological significance of RNAi as an antiviral mechanism in ESCs remains to 
be ascertained, it nonetheless provides a rational alternate for the deficiency of the IFN-
based antiviral mechanism in these cells.
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The molecular basis for a paradox of RNAi mechanism in mammalian cells
Biologically, the reason why somatic cells do not utilize RNAi can be rationally assumed to 
be that a powerful IFN-based innate immunity and adaptive immune system can effectively 
protect the cells from viral infection. As a result, the RNAi mechanism may no longer be 
necessary. However, at the molecular level, there is evidence indicating that the IFN-based 
antiviral mechanism and RNAi may have some conflict in their mechanisms of action, which 
appears to be due to the incompatibility between the IFN system and siRNA/miRNA 
biogenesis in differentiated cells.
miRNA are small non-coding RNA that regulate gene expression by silencing their target 
mRNA. In animals, miRNA share similar biogenesis and action model with siRNA, but their 
processing requires Drosha in addition to Dicer. miRNA or siRNA interacts with RISC, 
leading to the degradation of cellular mRNA or viral RNA through the catalytic activity of 
an Ago protein in the RISC complex.35 Multiple members of the Ago protein family with 
different functions are expressed in different species. The Ago proteins with endonucleolytic 
activity involved in RNAi in plants, fungi and invertebrates have been well-characterized.1 
Mammals express several Ago proteins, but most of them have lost the endonucleolytic 
activity, and only Ago2 is responsible for RNA cleavage in mammalian RISC.36 A study by 
Seo suggested that viral infection inhibited RISC activity via poly-ADP ribosylation of 
Ago2, indicating that RISC is no longer optimally engaged in RNAi as an antiviral 
mechanism in differentiated cells.37 The differences in siRNA and miRNA biogenesis in 
different organisms provide further molecular basis for their altered cellular functions. In 
insects, two Dicer proteins are expressed for miRNA and siRNA biogenesis, respectively, 
whereas somatic mammalian cells express a single Dicer that is optimized for miRNA 
processing, but is inefficient at processing long dsRNAs into siRNA.38 Therefore, current 
data support a conclusion that RNAi is unlikely to play a significant role in the overall 
antiviral immunity in developed mammalian species. Although this mechanism might be 
retained as a functional antiviral mechanism in ESCs in the absence of the IFN-based 
system,8,9 the molecular mechanism responsible for siRNA biogenesis remains to be 
determined.
IFN-based Antiviral Mechanism in ESCs
ESCs have underdeveloped IFN-based antiviral innate immunity
Based on the principle of the RNAi mechanism, synthetic siRNA have been developed as a 
powerful tool for gene silencing. In developing this technique, it was noted that long dsRNA 
can elicit the RNAi effect without adverse effects in the cells of invertebrate organisms, but 
they cause a global inhibition of translation and cell death in differentiated mammalian cells 
where long dsRNA are recognized as viral RNA and induce a strong IFN response. 
However, such cytotoxicity and IFN response were not apparent in ESCs.39 Thus, the lack of 
an IFN response was previously noted in ESCs, but it was not appreciated within the context 
of immunology.
One reason that has led to the revisiting of this subject stemmed from the finding that ESC-
derived endothelial cells, cardiomyocytes, smooth muscle cells, and osteoblasts have limited 
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immune responses to a wide range of infectious agents.40–43 This is markedly different from 
their in vivo counterparts isolated from tissues. These studies raised questions for the 
therapeutic application of ESC-derived cells, and also promoted studies seeking answers in 
the ESCs from which these cells are derived. Indeed, studies have found that both hESCs 
and mESCs lack immune responses to viral and bacterial pathogens typically seen in 
somatic cells, although they are susceptible to cytotoxicity of infection.41,42,44,44–49 The 
lack of IFN expression was also noted in mouse and human iPSCs.46,50 Together with the 
early findings,15–17 it is apparent that an underdeveloped innate immunity is a common 
feature of pluripotent cells as we have recently discussed.14
Significant progress has been made recently in understanding the underdeveloped IFN-based 
antiviral mechanisms in pluripotent cells. The conclusion for hESCs and hiPSCs is primarily 
derived from experiments using synthetic RNA, polyinosinic-polycytidylic acid (polyIC), as 
a viral RNA analog.46 In addition to synthetic RNAs (polyIC and long single stranded 
RNA), our studies with mESCs have used several live viruses, including La Crosse 
encephalitis virus, Chikungunya virus, West Nile virus, and Sendai virus.51–53 In all cases, 
mESCs were susceptible to viral infection, and none of the tested viruses induced IFN 
expression. Similarly, a study by Wash et al.49 demonstrated that mESCs can be infected 
with herpes simplex virus type 1 and influenza A virus, a dsRNA and ssRNA virus, 
respectively, and neither induced IFN expression.49
While the lack of IFN expression is strikingly similar in hESCs and mESCs, the IFN 
response mechanism in hESCs and mESCs is somewhat different. hESCs or hiPSCs fail to 
express ISGs when exposed to IFNβ,54 while mESCs could respond to IFNα and 
IFNβ.53,55,56 Furthermore, IFNα, IFNβ and IFNω can protect mESCs from the cytopathic 
effect of viral infection and inhibit replication of several types of viruses.51,53 However, the 
magnitude of response of mESCs to IFN is much weaker than fibroblasts. Therefore, the 
IFN response mechanism in mESCs is still significantly underdeveloped in comparison with 
differentiated cells isolated from mouse tissues51,53 (Figure 1).
The biological implications of an underdeveloped IFN-based antiviral mechanism in ESCs
The rationale for ESCs not to have a developed IFN system as in somatic cells is a complex 
question that we currently do not completely understand, but it can be considered from 
different perspectives. From the view of developmental biology, ESCs reside in the womb 
where they have limited exposure to pathogens. The mother’s immune system may offer 
them the necessary protection.57 A different hypothesis could be made based on the view 
that IFN are mainly produced for the purpose of defense with negative effects on 
proliferation of tissue cells. It would be logical for an early embryo not to produce these 
cytokines when cell proliferation and differentiation are major events.58 It is known that 
multiple forms of antiviral activities triggered by IFN can cause various adverse effects to 
the infected cells including cell death.2,33 While such effects may not cause much damage to 
a developed organism, the consequence could be detrimental to ESCs, the progenitors for all 
ensuing tissues of a developing organism. However, considering the fact that ESCs only 
exist transiently as part of the inner cell mass during early embryogenesis, whether or not an 
underdeveloped IFN system in ESCs is necessarily an issue remains an open question. 
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Further studies of the developmental stage- and tissue-specific expression of IFN, especially 
more direct in vivo experiments, are needed to elucidate the roles of the IFN system in 
reproduction and development.
The reciprocal inhibition between pluripotency and the IFN-based innate immunity in ESCs
There is clearly a “reciprocal inhibition” between the IFN system and pluripotency in ESCs 
that has been illustrated by the processes of in vitro ESC differentiation and reprogramming 
of fibroblasts to iPSCs. Our recent studies with mESCs have demonstrated that in vitro 
differentiation is characterized by mESCs losing pluripotency, concurrent with increased 
expression of viral RNA receptors and the gain of IFN expression capacity in mESC-
differentiated fibroblasts.51,53 Conversely, primary fibroblasts, which robustly express IFN 
in response to viral pathogens, lose this capacity after they are reprogrammed into iPSCs, 
with reduced expression of the signaling molecules essential for the IFN system,46,50 
meaning that gaining pluripotency is accompanied by the loss of IFN-based innate 
immunity.
From the perspective of developmental biology, the reciprocal inhibition between 
pluripotency and IFN-based innate immunity makes sense. It is logical for ESCs to repress 
the development of the IFN system to avoid potential adverse effects, or it may simply not 
be needed because of the protection by the mother’s immune system, as previously 
discussed. However, the results from iPSC reprogramming point to another possibility. Since 
iPSCs are pluripotent cells that are artificially generated in vitro, losing function of the IFN 
system is physiologically irrelevant to cellular innate immunity. It seems more likely that the 
IFN system is repressed during reprogramming because it may somehow conflict with 
molecular mechanisms that control pluripotency. While we do not fully understand why and 
how the reciprocal inhibition between the pluripotency and the IFN system is achieved, 
recent studies have provided convincing data to explain the deficiency of ESCs in expressing 
IFN and their attenuated response to these cytokines.
The molecular basis for deficient IFN expression in ESCs
The underdevelopment of IFN-based innate immunity is reflected at least at the receptor and 
transcription level. The major viral RNA receptors (TLR3, RIG-I and MDA5) are expressed 
at low levels in both hESCs and mESCs.46,52,52,59 Similar observations were made in 
iPSCs,46,50 which means that the ability to express IFN in the parental fibroblasts from 
which iPSCs were derived is reverted to the stem cell state after reprogramming. Therefore, 
the low expression level of viral RNA receptors in pluripotent cells is at least partially 
responsible for their lack of IFN expression.
Our recent study in mESCs has further demonstrated that NFκB is not activated by viral 
infection.51 This finding provides a direct link to the failure of these cells to express IFN at 
the transcription level, since NFκB is a key transcription factor that mediates the expression 
of IFN and inflammatory cytokines.60 In mammals, the NFκB family is composed of several 
transcription factors, but p50 and RelA subunits play a major role in mediating the immune 
response.61 In both mESCs and hESCs, RelA and p50 are expressed at low levels but are 
upregulated upon differentiation.62,63 It is particularly interesting to note that Nanog, one of 
Guo Page 7
Immunol Cell Biol. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the key pluripotency genes in ESCs, can bind to and inhibit NFκB transcriptional activity.64 
Another study has identified the mRNA of RelA as a target of miR-290 cluster, which 
belongs to a class of ESC-specific miRNA.65 A simplified conclusion from these findings is 
that NFκB is repressed in ESCs because its activation promotes differentiation and conflicts 
with pluripotency. Although these studies were not intended to investigate the role of NFκB 
in the immune and inflammatory responses in ESCs, the results in fact provide the molecular 
basis for the inactive status of NFκB and point to a new model of NFκB regulation unique to 
ESCs.
Since none of the above-mentioned studies were dedicated to investigating the role of NFκB 
in antiviral response in ESCs, we used a co-culture system where mESCs and mESC-
differentiated fibroblasts were infected with La Crosse encephalitis virus and Chikungunya 
virus. We demonstrated that NFκB is exclusively activated in mESC-differentiated 
fibroblasts, not in mESCs, by viral infection.51 The same observation was also reported in 
miPSCs that were infected with baculovirus.50 We propose that NFκB acts as a master 
switch that controls the antiviral response: it is switched off by the pluripotent state in ESCs 
and turned on by the process of differentiation.
The molecular basis for attenuated IFN responses in ESCs
While deficiency in the expression of IFN is common to both human and mouse ESCs and 
iPSCs, the IFN response mechanism in the two species differs to a certain degree. hESCs 
and hiPSCs fail to express ISGs when exposed to IFNβ.54 Although the major signaling 
molecules in the IFN response pathway are expressed at relatively lower levels than in 
differentiated human cells, the high expression level of suppressor of cytokine signaling 1 
(SOCS1, a negative regulator of the JAK/STAT signaling pathway66) seems to be the 
limiting factor for ISG induction in hESCs and hiPSCs.54 On the other hand, two early 
studies have reported that IFNα and IFNβ can induce expected responses in mESCs.55,56 
Our recent studies51,53 confirmed this finding in mESCs and provided several lines of 
evidence that mESCs have a functional IFN response mechanism: 1) the key signaling 
components that detect and mediate the effects of IFN are expressed, 2) IFNα and IFNβ 
induce ISG expression (ISG15, OAS1, and PKR), and 3) IFNα and IFNβ protect mESCs 
from the cytopathic effect of viral infection and repress replication of several types of 
viruses.51,53 While these results clearly demonstrate that mESCs can detect and respond to 
IFN, the level of response of mESCs and even mESC-differentiated fibroblasts to IFN is 
much weaker than that of naturally differentiated mouse fibroblasts, as judged by the levels 
of ISG induction and antiviral activity elicited by IFNα and IFNβ.51,53 Therefore, the 
response of mESCs to IFN is attenuated in comparison with differentiated cells.
Intrinsic antiviral immunity in ESCs
Limited information is available about the specific intrinsic antiviral factors in ESCs as 
described in somatic cells.30,31 However, the common intrinsic antiviral factor PKR is 
expressed in ESCs.46,52,67 In comparison with other viral RNA receptors in hESCs and 
mESCs, which are expressed at low levels, PKR is readily detected at both mRNA and 
protein levels. Both synthetic dsRNA (polyIC) and live viral infection activate PKR in 
mESCs, resulting in inhibition of cell proliferation as in somatic cells.52 Intriguingly, PKR is 
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not activated by polyIC in hESCs and hiPSCs, in which transfected polyIC seems to be 
sequestered in endosomes.46 While the role of PKR in the antiviral response in hESCs 
remains unclear, a recent study suggests that PKR is activated by cellular dsRNAs during 
mitosis and acts as a mitotic regulator.67
A few studies have investigated OAS and RNase L in ESCs. RNase L is expressed at a lower 
level in hESCs and hiPSCs than in HeLa cells and fibroblasts, but nevertheless is detectable 
at the protein level.46 Studies in mESCs showed that the mRNA of OAS1and RNase L are 
expressed at a moderate level.52,55 We have shown that OAS1 was strongly induced by La 
Crosse encephalitis virus infection in mouse fibroblasts, but not in mESCs. However, OAS1 
was induced by exogenously added IFNβ in mESCs.53 This is an interesting observation 
because it is relevant to a finding in somatic cells, in which it is believed that IFN are 
constitutively secreted at a low basal level as a means of keeping the cells at a “primed” 
state, so that they can mount a rapid and robust response to invading pathogens.68 We 
speculate that the failure of mESCs to express OAS1 in response to viral infection could be 
due to their deficiency in producing the basal level of IFN needed to keep them in a 
“primed” state. However, it is possible that the expression of OAS1 (or other ISGs for that 
matter) in mESCs could be higher in vivo since they can be “primed” by IFN secreted from 
other cells (such as trophoblasts of the placenta) via paracrine signaling.69 Although the 
contribution of OAS/RNase L and the PKR pathways to the antiviral activity in ESCs 
remains to be further investigated, there is a molecular basis that reasonably supports their 
potential roles in antiviral responses, at least in mESCs.
Differences in Antiviral Innate Immunity between hESCs and mESCs
mESCs and hESCs share fundamental similarities in self-renewal and pluripotency, which 
are controlled by a transcriptional network consisting of similar core transcription 
factors,10–12 but they nevertheless display a number of differences as in other aspects of the 
two species.70 Most notably, the stem cell state of mESCs is maintained by leukemia 
inhibitory factor (LIF), whereas FGF2 and activin A, but not LIF, are the primary 
determinants of hESC self-renewal and pluripotency.71,72 mESCs are characterized by a 
shortened cell cycle, whereas hESCs have a cell cycle time frame similar to that of 
differentiated cells.73,74 PKR activation and response to type I IFN represent the differences 
that so far have been noted between the two species in terms of innate immunity.46,52–54 The 
mouse models have generated a vast amount of data that remarkably mirrors human biology, 
but it is not surprising that notable differences in many aspects, including immunity, have 
been noted between the two species.75 Further understanding of the differences between 
hESCs and mESCs in innate immunity is an important issue not only for understanding 
basic developmental biology and immunology, but also for of ESC-based regenerative 
medicine.
Conclusions and Perspective
Along with the remarkable progress that has been made toward the application of ESCs in 
regenerative medicine, we have also witnessed how the discoveries made from stem cell 
research have led to a better understanding of many important questions in basic biology. It 
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has become apparent that ESCs and differentiated cells have distinct antiviral innate 
immunity. The two antiviral mechanisms established in differentiated cells, the IFN system 
and the intrinsic antiviral pathway, are both underdeveloped in ESCs. Most notably, the IFN 
expression and IFN response pathway is either absent or severely attenuated in ESCs (Figure 
1). What we have learned from ESCs clearly demonstrated that innate immunity is in fact 
not “innate” to ESCs; it is rather “acquired” and remolded during the process of organism 
development. While it is exciting to see that the findings from pluripotent cell models have 
already provided new insight into the evolution of RNA-based antiviral mechanisms in 
different organisms, much more investigation is needed to determine whether or not RNAi 
makes a physiologically meaningful contribution to the antiviral activity in ESCs and the 
early stages of organismal development in mammals. Along the line of this direction, it is 
particularly interesting to note that the recent discovery of miRNA as a new class of 
immunity modulators adds another layer of complexity to our understanding of the already 
sophisticated innate immune system.76 ESCs and iPSCs could once again be proven to be 
valuable models for such investigations.
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Figure 1. 
Schematic diagram of antiviral mechanisms in mammalian cells: IFN-based antiviral system, 
including IFN expression pathway (AE) and IFN response pathway (AR); the intrinsic 
antiviral pathway (B); and the RNAi antiviral pathway (C). The functionality of the 
pathways is denoted by: (++), fully developed; (+), partly developed; (−), not developed or 
severely attenuated; (?) uncertain or no sufficient data. DC, differentiated cells; ESC refers 
to both human and mouse ESCs. See the text for other abbreviations and further 
explanations.
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